<DOC>
	<DOCNO>NCT00960622</DOCNO>
	<brief_summary>Study subject receive antiretroviral drug Combivir trizivir , randomize switch Truvada-containing highly active antiretroviral therapy ( HAART ) continue Combivir trizivir . Measurements perform baseline 6 month randomization either continue trizivir combivir , switch Truvada . Measurements include maximal peak oxygen consumption , lactate production clearance , subcutaneous adipose tissue limb fat content , insulin resistance , liver muscle fat content , plasma free fatty acid concentration . The hypothesis underlie study chronic therapy thymidine analogue nucleoside reverse transcriptase inhibitor ( NRTIs ) , include zidovudine ( AZT ) , lead clinically detectable mitochondrial dysfunction several organ system .</brief_summary>
	<brief_title>Switch From Combivir Trizivir Truvada - Mitochondrial Effects</brief_title>
	<detailed_description>None different summary description .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>infection human immunodeficiency virus ( HIV ) undetectable viral load Combivir trizivir able exercise sign consent active illness contraindication magnetic resonance imaging ( MRI ) scan maximal exercise .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>treatment experience</keyword>
</DOC>